Usefulness of Granulocyte Colony-Stimulating Factor in Patients With a Large Anterior Wall Acute Myocardial Infarction to Prevent Left Ventricular Remodeling (The Rigenera Study)

Leone, Antonio Maria; Galiuto, Leonarda; Garramone, Barbara; Rutella, Sergio; Giannico, Maria Benedetta; Brugaletta, Salvatore; Perfetti, Matteo; Liuzzo, Giovanna; Porto, Italo; Burzotta, Francesco; Niccoli, Giampaolo; Biasucci, Luigi M.; Leone, Giuseppe; Rebuzzi, Antonio Giuseppe; Crea, Filippo

doi:10.1016/j.amjcard.2007.03.036

Cited by 56 publications

(41 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study confirmed the beneficial effects of G-CSF treatment, as reported in animals. Moreover, in patients with large anterior myocardial infarction and reduced left ventricular ejection fraction (LVEF), G-CSF led to better LVEF and a reduced LV end-diastolic diameter at the 5-month followup [69]. This effect on LVEF was observed in other clinical studies [70,71].…”

Section: Clinical Studiesmentioning

confidence: 86%

Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

2010

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic cytokine usually used in the treatment of patients with cancer. Studies have shown regenerative properties of bone marrow stem cell mobilization due to G-CSF in animals. Moreover, others effects related to G-CSF and independent of tissue regeneration were shown to be protective. As a result, this cytokine has been tested as a therapy for ischemic heart failure in humans. However, when this treatment was evaluated in clinical trials, the beneficial effects seen in small animals were not confirmed in infarcted patients. Thus, we sought to review the effects of G-CSF after an ischemic insult and on the progression of heart failure in animals and humans.

show abstract

Section: Clinical Studiesmentioning

confidence: 86%

Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

2010

View full text Add to dashboard Cite

show abstract

“…In another study, G-CSF was injected within 5 days post-AMI in 41 patients at high risk for unfavorable left ventricular remodeling. Five months after G-CSF treatment, ejection fraction had improved 12.5% compared to no improvement in the control group (Leone et al, 2007). The improvements in cardiac function appeared to be linked to the prevention of left ventricular remodeling.…”

Section: Acute Myocardial Infarctionmentioning

confidence: 78%

The Therapeutic Potential of Stimulating Endogenous Stem Cell Mobilization

Drapeau¹,

Eufemio²,

Mazzoni³

et al. 2012

Tissue Regeneration - From Basic Biology to Clinical Application

View full text Add to dashboard Cite

“…Only three trials have reported positive results. In the FIRSTLINE-AMI trial (Ince et al, 2005), the RIGENERA study (Leone et al, 2007) and in the study by Takano et al (Takano et al, 2007), significant improvements in LVEF were observed. The rest of the trials showed negative findings.…”

Section: Stem Cell Therapy After Acute Myocardial Infarctionmentioning

confidence: 99%

Randomized Clinical Trials in Stem Cell Therapy for the Heart - Old and New Types of Cells for Cardiovascular Repair

Sanz‐Ruiz¹,

Arranz²,

Ibañes³

et al. 2011

Stem Cells in Clinic and Research

View full text Add to dashboard Cite

Usefulness of Granulocyte Colony-Stimulating Factor in Patients With a Large Anterior Wall Acute Myocardial Infarction to Prevent Left Ventricular Remodeling (The Rigenera Study)

Cited by 56 publications

References 22 publications

Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

The Therapeutic Potential of Stimulating Endogenous Stem Cell Mobilization

Randomized Clinical Trials in Stem Cell Therapy for the Heart - Old and New Types of Cells for Cardiovascular Repair

Contact Info

Product

Resources

About